Method of treating dry eye disorders
View Patent ↗The topical use of EgLN-3 inhibitors is disclosed for the treatment of dry eye.
1. A method for the treatment of dry eye in a mammal, which comprises topically administering to the eye of the mammal a composition comprising a pharmaceutically acceptable carrier and 0.1-1% (w/v) of an inhibitor of the EgLN-3 enzyme, wherein the EgLN-3 inhibitor is selected from the group consisting of:
wherein:
R is H, C 1-6 straight chain or branched alkyl, phenyl, or benzyl, or CO 2 R forms a salt of formula CO 2 − M + , with M + being Li + , Na + , K + , or NH 4 + ; and
R 1 is H, C(O)CH 3 , or C(O)C 6 H 5 .
2. The method of claim 1 , wherein the compound is selected from the group consisting of:
wherein:
R is H, CH 3 , C 2 H 5 , or i-C 3 H 7 ; and
R 1 is H or C(O)CH 3 .
3. The method of claim 1 , wherein
R is H, CH 3 , C 2 H 5 , or i-C 3 H 7 ; and
R 1 is H or C(O)CH 3 .
4. The method of claim 1 , wherein the pharmaceutically acceptable carrier comprises one or more ingredients selected from the group consisting of surfactants; tonicity agents; buffers; preservatives; co-solvents; and viscosity building agents.